05:31 PM EDT, 08/20/2024 (MT Newswires) -- Azitra ( AZTR ) said late Tuesday that it has screened the first patient in its phase 1b trial of ATR-12 to treat Netherton syndrome, a chronic genetic skin disease.

The patient is scheduled to start treatment by the end of the month, the company said. It expects to enroll about 12 adult patients.

Azitra ( AZTR ) expects to report interim safety data in early 2025, with full results anticipated in H2 of the same year.

Shares of the company surged 60% in after-hours activity.

Price: 1.0200, Change: +0.38, Percent Change: +60.63